cPLA2–Inhibitor (stoPLA) – New compounds for the topical treatment of skin inflammation

Novel group of nonsteroidal anti-inflammatory drugs: The new class of heteroaryl-substituted acetone derivatives inhibits effectively the cytosolic phospholipase A2 (cPLA2).

The compounds interact with the synthesis of prosta-glandins and leukotrienes and reduce inflammatory processes. The substances have an excellent solubility profile. The heteroaryl-substituted acetone derivatives provide the platform for the development of new pharmaceutical products for the treatment of inflammatory diseases of the skin, such as psoriasis and atopic dermatitis.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Breakthrough in magnetism that could transform quantum computing and superconductors

Researchers discover new magnetic and electronic properties in kagome magnet thin films. A discovery by Rice University physicists and collaborators is unlocking a new understanding of magnetism and electronic interactions…

NASA to launch innovative solar coronagraph to Space Station

NASA’s Coronal Diagnostic Experiment (CODEX) is ready to launch to the International Space Station to reveal new details about the solar wind including its origin and its evolution. Launching in…

Boosting efficiency in mining with AI and automation

“Doing instead of procrastinating”. This is the AI strategy presented by Prof. Constantin Haefner, Director of the Fraunhofer Institute for Laser Technology ILT, at the “AKL’24 – International Laser Technology…